Yes, that was approximately a $500M market cap for a company that just finished an antibiotic phase 2B with flying colors against a comparator (Cubicin) that was pulling $1B/year. Additionally it had a cancer drug called Kevetrin that was PR'd to have caused a Spleen lesion to completely disappear in phase 1. Along with that we were heading rapidly toward a NASDAQ uplist, a cure for Psoriasis and a cure for OM. CTIX was arguably undervalued at $500M.
Of course the antibiotic market and the supposed miracles of Kevetrin ended up being over-hyped resulting in our crash back to earth.
The market has heard the $60-130B anti-viral market hype. It is now waiting for the B-COVID results. The market knows that the results will be spun in the most positive light. It will therefore apply the IPIX valuation penalty (that's divide what you expect by 5) until suitable monetization (lucrative partnership), buyout, or validation by a third party (FDA EUA) such that there is a rational reason to remove the IPIX valuation penalty.
News 
Market Data 
Discover 
AI
